Cell:科学家发现脑部疾病研究的新途径

2016-03-21 佚名 生物谷

大脑中被称为离子通道的某些蛋白质的目的是调节神经细胞如何发射或发送信息。但在最近发表于《Cell》的研究中,耶鲁大学领导的研究团队发现了一种特定通道的未知功能,当该通道突变时,会导致一种罕见的脑部疾病。他们的发现开辟了大脑研究的新途径。 Kv3.3通道中的突变会导致一种罕见的退行性疾病,该病会影响年轻患者甚至新生儿的平衡和活动性,但也可能发生在中年人身上。在一种突变的研究中,药理学教授Leona

大脑中被称为离子通道的某些蛋白质的目的是调节神经细胞如何发射或发送信息。但在最近发表于《Cell》的研究中,耶鲁大学领导的研究团队发现了一种特定通道的未知功能,当该通道突变时,会导致一种罕见的脑部疾病。他们的发现开辟了大脑研究的新途径。

Kv3.3通道中的突变会导致一种罕见的退行性疾病,该病会影响年轻患者甚至新生儿的平衡和活动性,但也可能发生在中年人身上。在一种突变的研究中,药理学教授Leonard Kaczmarek和共同作者们获得了一些意料之外的发现。与其他通道相比,Kv3.3通道有能力构建细胞骨架,一种组织和塑造细胞的结构。

他们还发现,为了实现这一点,该通道会与控制神经细胞生存或死亡的Hax-1蛋白质相互作用。"这是惊人的"Kaczmarek说,"之前认为这些通道不应该与细胞死亡蛋白质交互。这有点像突然发现你最好的朋友竟然做了20年的杀手。"

研究结果为疾病和大脑功能提供了新的见解。"关键的发现是,一种之前认为仅仅调节神经元如何发射的蛋白质其实拥有另一种功能:控制那些决定细胞生存或死亡的蛋白质的活性"Kaczmarek指出,"理解通道能够发挥这种功能,为我们提供了一组新的研究和治疗靶点。"

原始出处:

Yalan Zhang,Xiao-Feng Zhang,Matthew R.Fleming,et al.Kv3.3 Channels Bind Hax-1 and Arp2/3 to Assemble a Stable Local Actin Network that Regulates Channel Gating.Cell.DOI: 10.1016/j.cell.2016.02.009.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959572, encodeId=cd6719595e2fc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 04 20:02:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802309, encodeId=331d1802309b0, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Dec 31 04:02:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037399, encodeId=e3d3203e3999f, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Apr 09 02:02:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953357, encodeId=265a195335eff, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Feb 12 14:02:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070393, encodeId=825720e039391, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Feb 25 07:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869316, encodeId=9e9e18693160d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 25 13:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]
    2016-11-04 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959572, encodeId=cd6719595e2fc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 04 20:02:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802309, encodeId=331d1802309b0, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Dec 31 04:02:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037399, encodeId=e3d3203e3999f, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Apr 09 02:02:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953357, encodeId=265a195335eff, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Feb 12 14:02:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070393, encodeId=825720e039391, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Feb 25 07:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869316, encodeId=9e9e18693160d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 25 13:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959572, encodeId=cd6719595e2fc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 04 20:02:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802309, encodeId=331d1802309b0, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Dec 31 04:02:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037399, encodeId=e3d3203e3999f, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Apr 09 02:02:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953357, encodeId=265a195335eff, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Feb 12 14:02:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070393, encodeId=825720e039391, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Feb 25 07:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869316, encodeId=9e9e18693160d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 25 13:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959572, encodeId=cd6719595e2fc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 04 20:02:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802309, encodeId=331d1802309b0, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Dec 31 04:02:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037399, encodeId=e3d3203e3999f, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Apr 09 02:02:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953357, encodeId=265a195335eff, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Feb 12 14:02:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070393, encodeId=825720e039391, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Feb 25 07:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869316, encodeId=9e9e18693160d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 25 13:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959572, encodeId=cd6719595e2fc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 04 20:02:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802309, encodeId=331d1802309b0, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Dec 31 04:02:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037399, encodeId=e3d3203e3999f, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Apr 09 02:02:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953357, encodeId=265a195335eff, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Feb 12 14:02:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070393, encodeId=825720e039391, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Feb 25 07:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869316, encodeId=9e9e18693160d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 25 13:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1959572, encodeId=cd6719595e2fc, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Nov 04 20:02:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802309, encodeId=331d1802309b0, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Dec 31 04:02:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037399, encodeId=e3d3203e3999f, content=<a href='/topic/show?id=1af68515859' target=_blank style='color:#2F92EE;'>#脑部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85158, encryptionId=1af68515859, topicName=脑部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Apr 09 02:02:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953357, encodeId=265a195335eff, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Sun Feb 12 14:02:00 CST 2017, time=2017-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070393, encodeId=825720e039391, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Feb 25 07:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869316, encodeId=9e9e18693160d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 25 13:02:00 CST 2017, time=2017-02-25, status=1, ipAttribution=)]

相关资讯

基因编辑工具CRISPR“动物园”欢迎你

Timothy Doran的11岁女儿对鸡蛋过敏。全球约有2%的儿童患有这种病症。像他们一样,Doran的女儿无法接受很多常规疫苗接种,因为它们是利用鸡蛋生产出来的。 身为澳大利亚联邦科学和产业研究组织(CSIRO)分子生物学家的Doran觉得,他能通过强大的基因编辑工具CRISPR-Cas9解决这一问题。大多数鸡蛋过敏是由蛋清中的4种蛋白之一引起的。而当Doran的同事改变了细菌内编码其中

mBio:神奇!首次证实细菌释放挥发物促进真菌生长!

在一项新的研究中,法国研究人员发现一种细菌性病原体释放的挥发性化合物促进囊性纤维化(cystic fibrosis, CF)病人肺部感染中发现的真菌性病原体生长。这一发现首次证实一种病原体通过空气释放信号,从而直接促进另一种病原体生长。相关研究结果发表在2016年3月15日那期mBio期刊上,论文标题为“Volatile Compounds Emit

Nature Communications:科学家开发新方法将健康人类神经细胞注入大脑

罗格斯大学和斯坦福大学的科学家们创造出一种新技术,未来可能帮助治疗帕金森病和其他影响数百万人的毁灭性大脑相关疾病。 罗格斯大学生物医学工程系和化学与生化工程系特聘教授Prabhas V. Moghe表示,这种创新技术涉及将成人组织-衍生的干细胞在三维纤维"支架"或微小岛状物上转化为人类神经元。 这些装载健康、有益的神经元的支架,在被注入小鼠大脑后,能够替换病变细胞。 "如果你能以一种模拟细胞

J Neurosci :用极度饥饿的方式可预防神经退行性变

减少一个人的卡路里摄入量可以预防神经退行性疾病,如帕金森病。但这种现象发生的原因直到现在仍然是个谜。 莫纳什大学生物医学研究所的研究人员Zane Andrews副教授发现这种热量可降低神经保护作用——开放该类药物发展可以在不用减少卡路里摄入的情况下可减缓或防止帕金森等疾病。该研究发表在《神经科学杂志》上。 人类有一种激素称为胃促生长素或“饥饿激素”——在胃肠道产生,作用于大脑用以调节饥饿的

Mol Metabol:饮食多样性降低或影响机体肠道微生物群落的多样性

过去50年里人类耕种方式的改变导致了农作物多样性的降低,从而导致人类饮食多样性的降低,而饮食丰富度的改变对人类健康的明显影响就是如今科学家们非常热衷于研究的课题;近日一项刊登于Molecular Metabolism杂志上的报告中,来自路易斯安那州立大学潘宁顿生物医学研究中心(Pennington Biomedical Research Center)的研究人员就阐明了他们的最新研究成果。

AAC:细菌抗生素耐药性 挥之不去的社会问题

近日,来自纽约大学的研究人员通过研究发现,微量浓度的抗生素或许都足以促进细胞产生抗生素耐药性,研究者表示,这种浓度低于此前他们预期的抗生素浓度,这或可帮助解释为何抗生素耐药性在环境中会持久存在。 抗生素耐药性可以以不同方式来发挥作用,文章中研究者描述了抗生素单一作用及共同作用时耐药性所表现出的不同机制;单一的药物耐受性或许可以使得单一细胞具有耐受性,而共同合作的抗生素耐药性或许使得耐药性细胞及其